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Edited by Hans-Dieter KlenkAbstract Short-hairpin RNAs (shRNAs) inhibit gene expres-
sion by RNA interference. Here, we report on the inhibition,
by baculovirus-based vector-derived shRNAs, of core-protein
expression in full-length hepatitis C virus (HCV) replicon cells.
shRNAs were designed to target the highly conserved core region
of the HCV genome. In particular, the core-shRNA452 contain-
ing nucleotides 452–472, as the target in the HCV core gene,
dramatically inhibited the expression of the HCV core protein
in replicon cells. Furthermore, HCV core-protein expression
was inhibited more strongly by the vesicular stomatitis virus gly-
coprotein (VSV-G)-pseudotyped baculovirus vector than by the
wild-type baculovirus vector.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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glycoprotein1. Introduction
The hepatitis C virus (HCV) is a major cause of liver-related
morbidity and mortality [1]. The virus establishes a persistent
liver infection, leading to the development of chronic hepatitis,
liver cirrhosis, and hepatocellular carcinomas [1,2]. However, a
highly eﬀective anti-HCV drug has yet to be developed, partly
due to the lack of detailed information about the life cycle of
the virus. In an eﬀort to develop an alternative to combined
interferon–ribavirin treatment [3,4], we used RNA interference
(RNAi) based on short-hairpin RNA (shRNA), which is a
powerful tool for suppressing gene function [5]. RNAi is trig-
gered by small-interfering RNAs (siRNAs) that are processed
from long double-stranded or hairpin precursors, and become
part of the ribonucleoprotein complex, the RNA-induced
silencing complex (RISC) [6,7]. siRNAs expressed from
DNA templates through the action of the Dicer enzyme silence
gene expression as eﬀectively as exogenously introduced syn-
thetic siRNAs [5,8,9]. The use of RNAi has recently been ex-
tended to diﬀerentiated cultured mammalian cells [10]. It has*Corresponding author. Address: Department of Life and Environ-
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doi:10.1016/j.febslet.2008.07.056also been used to inhibit viral replication in the HCV subge-
nomic replicon [11–13].
The baculovirus Autographa californica nuclear polyhedrosis
virus (AcNPV) has long been used as a biopesticide, and as a
tool for eﬃcient recombinant protein production in insect cells
[14]. Its host speciﬁcity was originally thought to be restricted
to cells derived from arthropods; however, with an appropriate
eukaryotic promoter, it can express foreign genes in several
types of mammalian cells [15–17] and animal models [18,19].
Its advantages for use in gene-therapy applications are its
inherent inability to replicate, its lack of cytopathic eﬀect
(CPE) in mammalian cells even at a high multiplicity of infec-
tion (MOI), and the absence of preexisting antibodies against
baculoviruses in animals.
Here we designed baculovirus vector-mediated shRNAs
against the highly conserved core-protein region of the HCV
[20,21]. The shRNA452 construct mediated more eﬀective inhi-
bition of HCV replication than the other core-shRNAs (Ac-
shRNA479 and Ac-shRNA523). We also found that HCV
core-protein expression was more signiﬁcantly inhibited by
the vesicular stomatitis virus glycoprotein (VSV-G)-pseudo-
typed baculovirus vector than by the wild-type baculovirus
vector.2. Materials and methods
2.1. Baculovirus transfer vector constructs
We designed baculovirus transfer vectors expressing shRNAs
against the following regions of the HCV core-protein sequence: nucle-
otides 452–472, containing the nuclear localization signal site (pU6-
core-shRNA452); nucleotides 479–499 (pU6-core-shRNA479); and
nucleotides 523–543 (pU6-core-shRNA523) [22]. Sense and antisense
strands of shRNA oligonucleotides were synthesized, annealed at
95 C for 3 min, and then slowly cooled in phosphate-buﬀered saline
(PBS; pH 7.4, containing 50 mM NaCl). The oligonucleotides con-
tained the loop CCACACC sequence, and Kpn I and BamHI ends,
which were inserted into a pU6 vector, based on pSV2-neo. A Pol
III-type U6 promoter allowed the constant expression of shRNAs.
The following three sites in the core region of the common sequences
of the HCV strain M1LE (GenBank accession number AB080299)
were chosen as the targets for shRNAs: 5 0-GCCGCGCAGGGGCCC-
CAGGUU-3 0 (shRNA452); 5 0-GCGCGCGACUAGGAAGACUUC-
3 0 (shRNA479); and 5 0-GCGACAACCUAUCCCCAAGGC-3 0
(shRNA523). Fragments of U6-core-shRNAs, ranging from the Eco-
RI site upstream of the U6 promoter to the BamHI site downstream
of the terminating sequences, were sequenced and then inserted into
the cloning site of the baculovirus transfer vector, pVL1393 (BD Bio-
sciences, San Jose, CA, USA) in an opposite orientation to the PH pro-
moter (Fig. 1C), in order to create pVL1393-core-shRNA452,
shRNA479, shRNA523, and pVL1393-U6-terminator. A spacer was
inserted between the inverted sequences to form a hairpin structure,blished by Elsevier B.V. All rights reserved.
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Fig. 1. (A) Genomic proﬁle of HCV showing both coding and non-coding genes. (B) HCV core-region target sites and sequences used for the design
of shRNAs. (C) Construction and schematic representation of baculovirus transfer vector expressing HCV core-shRNA.
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shRNA) cloned into the same vector was used as a negative control
(pVL1393-control-shRNA) in all experiments. The VSV-G-pseudo-
typed baculovirus vector-transduced shRNA452 was constructed fol-
lowing previously published procedures [23].
2.2. Preparation of baculoviruses
Recombinant baculovirus containing the shRNA genome (Ac-
shRNA) was generated by homologous recombination of the transfer
vector and linearized baculovirus DNAs (BD Biosciences) following
previously published procedures [23].
2.3. Cell culture
NNC#2 (NN/1b/FL) cells [24] carrying a full genome replicon were
cultured in Dulbeccos modiﬁed Eagles medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), non-essential amino-acids,
L-glutamine, and 1 mg/ml G418 (Invitrogen, Carlsbad, CA, USA).
2.4. Measurement of HCV core protein
AcU6-HCV-core-shRNAs or AcU6-VSV-HCV-core-shRNAs were
used to infect HCV replicon cells. After 48 h, intracellular HCV
core-protein levels were measured using a fully automated HCV
core-protein antigen chemiluminescent enzyme immunoassay (CLEIA)
according to the manufacturers instructions [25]. The relative chemilu-
minescence unit was measured, and was used to determine the concen-
tration of HCV core antigen according to a standard curve generated
using recombinant HCV core antigen. The concentration was ex-
pressed in units of femto-mol/L (fmol/L). Each CLEIA assay was per-
formed in triplicate.3. Results
3.1. Construction of baculovirus transfer vectors carrying
shRNA-synthesizing cassettes
The core-protein forms the nucleocapsid, and modulates
gene transcription, cell proliferation, and apoptosis [21].
HCV functions as a messenger RNA (mRNA) with a single-
stranded RNA genome; thus, we hypothesized that cleavage
of the core-protein mRNA would inhibit nuclear transport
and virus duplication.
To characterize the eﬃciency of baculoviruses as vehicles for
gene therapy, we selected the HCV core region as a target site
(Fig. 1A and B), and constructed a recombinant baculovirusvector expressing the shRNA. Fig. 1C shows the baculovi-
rus-transfer vectors used in this study. The baculovirus-trans-
fer vector pVL1393-core-shRNA carries core-shRNA under
the control of the PolIII, U6 promoter. Recombinant baculo-
virus containing the shRNA genome (Ac-shRNA) was gener-
ated by homologous recombination of the transfer vector
and linearized baculovirus DNAs (BD Biosciences) in Sf9 cells.
Viruses were produced at high titers, ranging from 1.5 · 108 to
1.2 · 109 pfu/ml. shRNA452 expression was conﬁrmed by
Northern blot analysis in Ac-shRNA452-infected Huh-7 cells
(Supplementary Fig. S1 and Supplementary methods).
3.2. Inhibition of HCV RNA replication of baculovirus-mediated
shRNA-expression vectors in the HCV replicon
We investigated whether intracellular expression of shRNA
inhibited viral replication and aﬀected HCV RNA levels in
NNC#2 cells. The baculovirus-infection eﬃciency of NNC#2
cells ranged from 80 to 90% (Fig. 2A and Supplementary
methods). The real-time reverse-transcription (RT) polymerase
chain reaction (PCR) was used to examine the presence of
HCV RNA, and the ability to induce RNA silencing in
NNC#2 cells 48 h post-infection. When NNC#2 cells were in-
fected with Ac-shRNAs at a MOI of 100, a signiﬁcant reduc-
tion in HCV RNA levels was observed compared with a
non-related shRNA control (Fig. 2B and Supplementary
methods). Although inhibition of HCV RNA levels occurred
with all three constructs, the greatest eﬀect occurred with
sh452 (68%), while sh479 decreased the levels by approxi-
mately 55% and sh523 by 25%. By contrast, the control bacu-
lovirus vectors (Ac-U6-terminator and Ac-control-shRNA
[random sequence]) had no inhibitory eﬀect on HCV replica-
tion (Fig. 2B). These results point to a sequence-speciﬁc inhib-
itory eﬀect of shRNA on HCV replication.
3.3. Silencing of HCV core-protein expression through
baculovirus-mediated shRNA in the HCV replicon
We conﬁrmed the inhibitory eﬀect of shRNAs using ﬂuores-
cence microscopy to assess the localization and expression of
the HCV core protein 48 h post-infection. The core proteins
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Fig. 2. Inhibition of HCV RNA by baculovirus-mediated shRNA expression vector. (A) Fluorescence-microscopic analyses of HCV full replicon
cells (NNC#2, 4 · 104 cells/well) infected with enhanced green ﬂuorescent protein (EGFP) baculovirus (Ac-CMV-EGFP) at a MOI of 100. Images
were taken at a ·10 magniﬁcation 2 d post-infection: (a) Ac-CMV-EGFP; (b) NNC cells alone. (B) Real-time PCR analysis of HCV RNA expression
after transduction of HCV full replicon cells (NNC#2, 4 · 104 cells/well) with a MOI of 100 for baculovirus-mediated shRNA. Relative HCV RNA
values are shown. Error bars represent S.E. of the mean from three diﬀerent experiments. *P < 0.01; **P < 0.05.
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sh479, and sh523)-expressing NNC#2 cells (Fig. 3A and Sup-
plementary methods), as well as control cells (control-
shRNA). Inhibition of the HCV core protein was observed fol-
lowing infection by all three constructs, although the greatest
eﬀect occurred with sh452.
We next examined whether shRNA against the HCV core
protein inhibited viral replication, using a CLEIA assay. When
NNC#2 cells were infected with Ac-shRNAs at MOIs of 100
and 200, a signiﬁcant reduction in core-protein expression
was observed compared with a non-related shRNA controlDIC
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Fig. 3. Suppression of HCV core protein by baculovirus-mediated core-shR
HCV core-protein antibody (green) following infection of NCC#2 cells with
control-shRNA vector; (e) U6-terminator vector; (f) NNC cells alone. (B) Ac
protein levels were measured after 48 h by an HCV protein antigen CLEI
experiments. *P < 0.01; **P < 0.05.(Fig. 3B). The sh452 construct mediated more eﬀective inhibi-
tion of HCV replication than the other core-shRNAs (Ac-
shRNA479 and Ac-shRNA523). The control-Ac-U6-termina-
tor and Ac-control-shRNA baculovirus vectors had no inhib-
itory eﬀect on HCV replication.
Furthermore, enhanced gene-transfer eﬃciency was ob-
served in a range of cell lines with recombinant baculovirus
vectors expressing surface glycoprotein G of VSV-G (Fig.
4A). VSV-G enhances the escape of baculovirus vectors from
intracellular endosomes, thereby increasing the transduction
eﬃciency of the virus [17]. The VSV-G-modiﬁed baculovirusMOI 100 MOI 200
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Fig. 4. Inhibition of HCV core protein by VSV-G-pseudotyped and
wild-type baculovirus-mediated shRNAs. (A) Construction and
schematic representation of VSV-G-pseudotyped baculovirus transfer
vector expressing HCV core-shRNA. (B) CLEIA analysis of HCV
core-protein expression after transduction of HCV full replicon cells
(NNC#2, 4 · 104 cells/well) with Ac-shRNA452 (MOI = 100 [solid
circle] or 200 [solid triangle]), Ac-VSV-G-shRNA452 (MOI = 100
[open circle]) or control-shRNA expression vector (MOI = 100 [solid
diamond]).
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published procedures [23]. Based on the shRNA452-expression
data, we evaluated the eﬀectiveness of shRNA452-mediated
inhibition of HCV core expression by VSV-G-pseudotyped
or wild-type baculovirus vector-transduced shRNA in
NNC#2 cells. When Ac-VSV-G-shRNA452 (MOI = 100) or
Ac-shRNA452 (MOI = 00 or 200) was added to the cells at
3 d intervals for 12 d, a signiﬁcant reduction in HCV RNA
(70–90%) was sustained from day 3 to day 12. The results indi-
cated that HCV core protein expression was more strongly
inhibited by the VSV-G-pseudotyped baculovirus vector than
by the wild-type baculovirus vector (Fig. 4B). The ability of
Ac-VSV-G-shRNA452 to reduce HCV core-protein levels
was not due to a cytotoxic eﬀect (Supplementary Fig. S2 and
Supplementary methods).4. Discussion
There is a need for a highly eﬀective anti-HCV drug to be
developed. The current study aimed to establish a universal
baculovirus vector for intracellular shRNA generation and
inhibition of HCV gene expression in NNC#2 cells. shRNAs
that were designed to target core regions of HCV repliconRNA varied in their ability to inhibit HCV replication. It is
important to note that the core protein is synthesized as the
initial polypeptide from the HCV polyprotein precursor. How-
ever, the inhibition of the HCV core protein upon the intro-
duction of siRNAs was not determined in these studies
[11,12]. Our current work revealed that baculovirus-mediated
shRNA452 expression signiﬁcantly inhibits HCV replication.
The delivery of siRNA to appropriate cells or tissues is a ma-
jor challenge. Several approaches have been described for gen-
erating loss-of function phenotypes in mammalian systems
using siRNA; however, these techniques are limited and are
not suitable for generating a long-term silencing eﬀect in vivo
[26,27]. Eﬃcient and safe delivery systems have not yet been
established for the suppression of HCV replication. Baculovi-
ruses appear to be useful viral vectors, not only for the abun-
dant expression of foreign genes in insect cells, but also for
eﬃcient gene delivery to the hepatoma lines HepG2 and
Huh7 [28], and the osteogenic sarcoma line Saos2 [29].
In this study, the introduction of three diﬀerent baculovirus-
mediated shRNAs into target cells containing HCV replicon
RNA caused a dose-dependent reduction in the level of viral
proteins and RNA. In particular, protein-expression analyses
revealed that shRNA452 at a MOI of 200 suppressed HCV
core-protein levels by 75%. By contrast, the control baculovi-
rus vectors (Ac-U6-terminator and Ac-control-shRNA) had
no inhibitory eﬀect on HCV replication. We also examined
the suppression of HCV core protein by VSV-G-pseudotyped
baculovirus-mediated shRNA452. HCV core-protein expres-
sion was more strongly inhibited by the VSV-G-pseudotyped
baculovirus vector than by the wild-type baculovirus vector
(Fig. 4B). Baculovirus vectors carrying shRNA thus appear
to be able to inhibit HCV replication more eﬀectively than sim-
ple siRNA.
In conclusion, we have demonstrated eﬃcient inhibition of
intracellular HCV replication by baculovirus-based shRNA-
expressing vectors. The reduction in the amount of HCV
mRNA is consistent with an shRNA-mediated degradation ef-
fect at the post-transcriptional level; this suggests that our
RNAi approach might provide eﬀective gene therapy for
HCV infection, especially at the nuclear localization signal site
(the shRNA452 target site) within the conserved core region.
Furthermore, the VSV-G-modiﬁed baculovirus (Ac/VSV-G)
transduced genes into NNC#2 cells more eﬃciently than
wild-type baculovirus.
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